HomeCompareCPQQ vs PFE

CPQQ vs PFE: Dividend Comparison 2026

CPQQ yields 38834.95% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPQQ wins by $3.858848549159329e+22M in total portfolio value
10 years
CPQQ
CPQQ
● Live price
38834.95%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.858848549159329e+22M
Annual income
$38,394,003,937,925,745,000,000,000,000.00
Full CPQQ calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CPQQ vs PFE

📍 CPQQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPQQPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPQQ + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPQQ pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPQQ
Annual income on $10K today (after 15% tax)
$3,300,970.87/yr
After 10yr DRIP, annual income (after tax)
$32,634,903,347,236,885,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CPQQ beats the other by $32,634,903,347,236,885,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPQQ + PFE for your $10,000?

CPQQ: 50%PFE: 50%
100% PFE50/50100% CPQQ
Portfolio after 10yr
$1.9294242745796646e+22M
Annual income
$19,197,001,968,962,873,000,000,000,000.00/yr
Blended yield
99.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CPQQ
No analyst data
Altman Z
2.4
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPQQ buys
0
PFE buys
0
No recent congressional trades found for CPQQ or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPQQPFE
Forward yield38834.95%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$3.858848549159329e+22M$49.6K
Annual income after 10y$38,394,003,937,925,745,000,000,000,000.00$26,258.71
Total dividends collected$3.857570614184309e+22M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CPQQ vs PFE ($10,000, DRIP)

YearCPQQ PortfolioCPQQ Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$3,894,195$3,883,495.15$9,153$693.39+$3.89MCPQQ
2$1,417,539,494$1,413,372,705.07$8,593$849.25+$1417.53MCPQQ
3$482,345,463,493$480,828,696,234.49$8,336$1,066.78+$482345.46MCPQQ
4$153,423,906,840,973$152,907,797,195,035.16$8,437$1,384.80+$153423906.83MCPQQ
5$45,619,062,198,806,640$45,454,898,618,486,800.00$9,013$1,875.40+$45619062198.80MCPQQ
6$12,680,175,840,729,412,000$12,631,363,444,176,690,000.00$10,306$2,680.72+$12680175840729.40MCPQQ
7$3,294,863,542,749,988,000,000$3,281,295,754,600,407,600,000.00$12,820$4,101.38+$3294863542749988.00MCPQQ
8$800,370,327,599,482,000,000,000$796,844,823,608,739,400,000,000.00$17,673$6,826.70+$800370327599481984.00MCPQQ
9$181,758,461,371,541,470,000,000,000$180,902,065,121,010,000,000,000,000.00$27,543$12,591.86+$181758461371541454848.00MCPQQ
10$38,588,485,491,593,295,000,000,000,000$38,394,003,937,925,745,000,000,000,000.00$49,560$26,258.71+$3.858848549159329e+22MCPQQ

CPQQ vs PFE: Complete Analysis 2026

CPQQStock

China Power Equipment, Inc., through its An Sen (Xi'an) Power Science & Technology Co., Ltd. subsidiary and its affiliated operating company, Xi'an Amorphous Alloy Zhongxi Transformer Co., Ltd., engages in the design, manufacture, and distribution of amorphous alloy transformer cores and amorphous alloy distribution transformers in the People's Republic of China. Its devices are used to step down voltage at the final phase of the distribution of electricity to consumers, businesses, and industries. The company offers its products to electricity generators and suppliers, suppliers of electrical equipment, and other electric power transformers manufacturers. China Power Equipment, Inc. was founded in 2004 and is headquartered in Jingyang, the People's Republic of China.

Full CPQQ Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CPQQ vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPQQ vs SCHDCPQQ vs JEPICPQQ vs OCPQQ vs KOCPQQ vs MAINCPQQ vs JNJCPQQ vs MRKCPQQ vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.